A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

Clinical trial NCT06769412 · COMPLETED

Trial details

NCT number: NCT06769412
Sponsor: Regeneron Pharmaceuticals
Status: COMPLETED
Study type: OBSERVATIONAL

Retinal Vasculitis

Start date: 2025-07-01
Primary completion: 2025-08-15
Enrollment: 550000

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.